Lower costs boost Wyeth earnings - MarketWatch

Washington Post

Lower costs boost Wyeth earnings MarketWatch Wyeth's revenue from overseas sales of the rheumatoid arthritis drug Enbrel rose 6% to 6 million, while US and Canadian revenue amounted to 4 million, ... Drugmaker Wyeth posts 13 percent jump in 2Q profitThe Associated Press Wyeth 2Q Earnings Up 13% On Cost Cuts; View RaisedWall Street Journal all 360 news articles »

Amgen 2Q Profits Rise 40%; Boosts 2009 View >AMGN - Wall Street Journal

RTT News

Amgen 2Q Profits Rise 40%; Boosts 2009 View >AMGN Wall Street Journal ... he said, after concerns that the job losses and other effects of the recession had damped earlier patient demand for the rheumatoid arthritis medicine. ... GSK to Pay 0M for Commercial Rights to Amgen's Lead mAbGenetic Engineering News (press release) Amgen to Collaborate With GlaxoSmithKline to Commercialize ...PipelineReview.com (press release) Amgen reports higher earnings, deal with GlaxoMarketWatch (press release) Trading Markets (press release) all 236 news articles »

Bristol-Myers, Wyeth Post Higher 2Q Profits >BMY WYE - Wall Street Journal

MiamiHerald.com

Bristol-Myers, Wyeth Post Higher 2Q Profits >BMY WYE Wall Street Journal Johnson & Johnson (JNJ), for example, will pay royalties for its use of Medarex technology in two new drugs for psoriasis and rheumatoid arthritis. ... BMS to Shell Out .4B for MedarexGenetic Engineering News (press release) BMS buys Medarex for .1 billionPharmafocus all 449 news articles »

US agency warns Canadian drug giant of 'serious deficiencies' - Ottawa Citizen

US agency warns Canadian drug giant of 'serious deficiencies' Ottawa Citizen ... including multiple batches of "therapeutically significant" drugs to relieve pain, prevent seizures and treat the symptoms of rheumatoid arthritis. ... and more »